Trispan Drug Interactions

Enzyme inducers e.g. barbiturates, phenytoin, primidone, rifampicin, reduce the glucocorticoid effect.
Oestrogens (e.g. ovulation inhibitors) can enhance the clinical effect of Trispan.
Non-steroidal anti-inflammatory agents (e.g. salicylates, indometacin): The risk of gastrointestinal ulcerations and bleeding may be increased.
Oral antidiabetics and insulin: The hypoglycaemic effect is reduced.
Oral anticoagulants (coumarin derivatives) are attenuated in their effect; adjustment of the anticoagulant dose is required during concomitant use.
ACE inhibitors: If co-administered, there may be an increased risk that blood count changes may occur.
Atropine and other anticholinergics: A further increase in intraocular pressure cannot be excluded with concomitant use of Trispan.
Cardiac glycosides: Potassium deficiency may potentiate their effect.
Saluretics: In concomitant use, there is further potassium excretion.
Laxatives: The potassium loss may be accentuated.
Praziquantel: As a result of corticosteroids, a decrease in the blood concentration of praziquantel is possible.
Chloroquine, hydroxychloroquine, mefloquine: During concomitant use, there is an increased risk that myopathies and cardiomyopathies may occur.
Somatropin: The effect of somatropin can be reduced during long-term administration of Trispan.
Thyroid diagnostics: When protirelin is given, the rise in TSH may be reduced.
Ciclosporin: The blood levels of ciclosporin are increased; increased risk of cerebral seizures.
Paediatric population: Interaction studies have only been performed in adults.